SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is surging as the community rallies around the 'OG meme' narrative, evoking a sense of nostalgia and shared internet history. Fuelled by a wave of bullish sentiment, community members are expressing strong conviction. The community believes $RAGE represents a cultural movement, with many anticipating a 'moonshot'.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending amid shareholder Shah Capital's call for the company's sale, citing poor vaccine sales despite the potential of their combo partnership and a previous successful partnership after a similar call. The community is actively discussing buyout possibilities, potential acquirers, and the management's performance, while recalling past events where Shah's involvement led to positive outcomes. The focus remains on the potential sale and the impact on Novavax's valuation.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending due to its partnership with NVDA to co-develop GaN & SiC power semiconductors for NVIDIA’s 800V AI factory systems, sparking significant after-hours volume. The community is discussing potential price targets and whether the stock will experience a short squeeze, recognizing NVTS's role in powering the AI boom. With a focus on long-term AI infrastructure, traders are closely watching valuation and revenue potential.

Nova Minerals Ltd. engages in the exploration and development of mineral properties. Its projects include Estelle Gold, RPM, Korbel, Train, Stoney and Studies projects. The company was founded in January 1987 and is headquartered in Melbourne, Australia.

Nova Minerals Limited - ADR

Nova Minerals is trending due to positive updates on their Alaskan gold and antimony project, including high-grade gold assay results and news of extinguished debt, sparking investor interest. The community is discussing the company's potential to benefit from increased antimony prices and its undervalued status compared to peers. There is also speculation about the company receiving government grants to develop a domestic antimony supply chain.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst is trending as investors discuss the company's acquisition of Astria Therapeutics for $700M, a move aimed at bolstering their HAE portfolio with a late-stage, long-acting plasma kallikrein inhibitor; navenibart. Community chatter revolves around the deal's financial implications, potential dilution, and the strategic shift from in-house development to acquisitions, with some expressing concerns over increased debt and the timeline for potential returns while others are optimistic about the company's strengthened position in the HAE market.

Greenwave Technology Solutions, Inc. is an emerging growth company, which engages in recycling ferrous metal. It also recycles nonferrous metals including aluminum, copper, stainless steel, nickel, brass, titanium, lead, alloys, and mixed metal products. The company was founded on April 26, 2013 and is headquartered in Chesapeake, VA.

Greenwave Technology Solutions Inc

Greenwave Technology Solutions Inc is trending due to strong premarket action and discussions around potential catalysts. Community members are actively discussing the stock's low float and potential for significant price movement, with some expressing concerns about possible dilution and reverse splits. The broader context involves interest in metal recycling and related sectors, contributing to the stock's current buzz.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending due to positive community sentiment surrounding non-dilutive funding and the potential for Phase 3 trials, particularly for CAN-2409 in NSCLC. Discussions also highlight the upcoming CAN-3110 data release and its potential impact on the company's valuation. Some are speculating about potential partnerships and buyout opportunities.

American Resources Corp. engages in the extraction, processing, transportation, and distribution of metallurgical coal to the steel industry. It focuses on the operation of coal mining complexes located primarily within Pike, Knott, and Letcher Counties, Kentucky, and Wyoming County, West Virginia. The company was founded in 2006 and in headquartered in Fishers, IN.

American Resources Corporation - Ordinary Shares - Class A

American Resources Corporation ($AREC) is trending due to ongoing discussions around rare earth elements and critical minerals, particularly following news of a $33M financing deal. The community is debating the implications of potential dilution versus the benefits of increased capital for expansion, especially regarding ReElement Technologies and government interest. Some investors express concerns about past performance and management, while others are optimistic about the company's role in the domestic rare earth supply chain and potential for a ReElement IPO.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community debates its recent price volatility and potential support levels, with some anticipating a drop below $100K while others foresee a sharp reversal and new highs. Discussions also involve the impact of potential trade wars and broader macroeconomic factors on BTC's price action. Some traders point to technical indicators and whale activity as drivers of current market movements.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals ($CRML) is trending as discussions revolve around its potential role in securing a domestic rare earth supply amid U.S.-China trade tensions. Community members are speculating on possible government funding and the impact of policy changes, highlighting the company's Greenland mine and the undervalued rare earth sector. Some traders are pointing to technical indicators, comparing it to other trending stocks, and expressing optimism for continued upward movement.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates

Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.

Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of +800.00% and +37.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?

Ironwood Pharmaceuticals shares dropped 14.6% on Wednesday after the company reported a steep revenue miss in the first quarter, attributing the shortfall to a timing shift in rebates related to its gastrointestinal drug Linzess.&nbsp;The company maintained its full-year guidance and noted progress on a strategic review and pipeline development.The stock closed at $0.79, down $0.13 on Wednesday, and remained flat in after-hours trading.Ironwood posted Q1 2025 revenue of $41.1 million, down from $74.9 million a year earlier and well below the $56.7 million consensus estimate.&nbsp;GAAP net loss widened to $37.4 million, or $0.23 per share, compared to $0.03 per share in the year-ago quarter. Non-GAAP net loss came in at $0.14 per share.The company attributed the revenue decline to a change in gross-to-net rebate reserve estimates from partner AbbVie, which impacted the phasing of&nbsp;Linzess's U.S. net sales but is not expected to affect full-year results.&nbsp;Collaboration revenue related to Linzess dropped 46% year-over-year to $38.8 million.Ironwood reaffirmed its 2025 U.S. Linzess net sales forecast of $800 million to $850 million and raised its adjusted EBITDA outlook to over $105 million.&nbsp;Prescription demand for Linzess rose 8% year-over-year in Q1, in line with expectations. The company ended the quarter with $108.5 million in cash and cash equivalents, up from $88.6 million at year-end.Management said it will focus on maximizing shareholder value, including through a planned confirmatory Phase 3 trial for apraglutide and an ongoing strategic alternatives review with Goldman Sachs.Analyst sentiment soured as Wells Fargo downgraded the company to 'Equalweight' from 'Overweight,' slashing its price target from $7 to $1, according to Koyfin.Similarly, Jefferies downgraded Ironwood to 'Hold' from 'Buy,' lowering its target from $8 to $0.70, Koyfin data said.&nbsp;On Stocktwits, sentiment was ‘bearish’ amid ‘normal’ message volume.&nbsp;Some users criticized the lack of an earnings call, with one remarking that the company simply dropped the earnings release without discussion — a departure from its decade-long tradition — and instead chose to present at a life sciences conference later in the day.&nbsp;<stembedurl>https://stocktwits.com/TeeMan123/message/613768926</stembedurl><stembedurl>https://stocktwits.com/TeeMan123/message/613804225</stembedurl>Another user noted there was little new information in the earnings release beyond what had already been disclosed on April 25,&nbsp;saying they took advantage of the post-earnings selloff to add shares at a 12% discount.<stembedurl>https://stocktwits.com/Bio_Invest101/message/613802455</stembedurl>Shares of Ironwood have fallen 81.7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Ironwood Pharma Stock Draws Retail Investor Ire With Big Q1 Miss And No Earnings Call

The drugmaker’s first-quarter revenue of $41.1 million came in well below the consensus estimate of $56.7 million, attributed to changes in AbbVie’s gross-to-net rebate reserves. 

Equity

Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday...

Millrose Properties Set to Join S&P SmallCap 600

Millrose Properties Set to Join S&P SmallCap 600 Millrose Properties Set to Join S&P SmallCap 600 PR Newswire NEW YORK, Feb. 5, 2025 NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Millrose Properties Inc...

Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today...

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London...

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. LINZESS continued to deliver robust...

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

IRWD
Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IRWD News

IRWDIronwood Pharmaceuticals Inc - Ordinary Shares - Class A